story of the week
PIK3CA Mutations Associated With Lower Response in HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
J. Clin. Oncol 2014 Oct 10;32(29)3212-20, S Loibl, G von Minckwitz, A Schneeweiss, S Paepke, A Lehmann, M Rezai, DM Zahm, P Sinn, F Khandan, H Eidtmann, K Dohnal, C Heinrichs, J Huober, B Pfitzner, PA Fasching, F Andre, JL Lindner, C Sotiriou, A Dykgers, S Guo, S Gade, V Nekljudova, S Loi, M Untch, C DenkertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.